LanC like glutathione S-transferase 2Genealiases: GPR69B · TASP
Q-omics provides the consensus-scored LANCL2 profile across patient tissues and cancer cell-line models. LANCL2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LANCL2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, LANCL2 RNA expression shows 19,501 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, HNSC, and ACC as cancer lineages where LANCL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LANCL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LANCL2 survival associations across molecular data types. LANCL2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LANCL2 RNA expression–survival associations across cancer types. High LANCL2 expression shows unfavorable associations in STAD, KICH, MESO and SKCM, but favorable associations in KIRC and OV. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for LANCL2 RNA expression.
This table summarizes LANCL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LANCL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LANCL2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, STAD and CHOL. The HNSC box plot shows higher LANCL2 RNA expression in tumor versus normal tissue (log2 FC = +0.953, t-test p < 0.001).
This table shows molecular features associated with LANCL2 in patient tissues and cancer cell lines. In patient samples, LANCL2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LANCL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
